share_log

Needham Downgrades Cogent Biosciences to Hold, Maintains Price Target to $15

Needham Downgrades Cogent Biosciences to Hold, Maintains Price Target to $15

Needham将Cogent Biosciences的评级下调为持有,维持价格目标为15美元
Benzinga ·  2024/12/11 20:18  · 评级/大行评级

Needham analyst Ami Fadia downgrades Cogent Biosciences (NASDAQ:COGT) from Buy to Hold and maintains the price target from $15 to $15.

Needham分析师Ami Fadia将Cogent Biosciences(纳斯达克:COGT)的评级从买入下调至持有,并将价格目标维持在15美元不变。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发